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Abstract: Myostatin, along with its binding protein follistatin, have been demonstrated to inhibit skeletal muscle development during
embryonic and postnatal development, whereas IGF-1 has been reported to stimulate skeletal muscle development and overall
growth. The objectives of the current study were to determine the expression profiles of myostatin and follistatin genes, and to
evaluate the impact of in ovo administration of recombinant human insulin-like growth factor-1 (rhIGF-1) on these gene expression
patterns during quail embryogenesis, with an emphasis on skeletal muscle development. Quail eggs were injected once with 100 ng
rhIGF-1 in 10 mM acetic acid, 0.1% BSA per embryo on day 3 of embryonic development. Total RNA was isolated from whole
embryos on each of embryonic days (E) 3 to 6 (n = 6 per day/per treatment), from thoracic/abdominal halves of the embryos on E
7 and E 8 (n = 6 per day/per treatment), and from pectoralis muscle tissues on Es 9 to 16 (n= 4 per day/per treatment). Reversetranscription polymerase chain reaction (RT-PCR) was used to determine the relative expression pattern. Myostatin mRNA was first
detected on E 5, while follistatin mRNA was first detected on E 3. Although myostatin mRNA levels from the control group declined
from E 10 to E 12, they increased from E 9 to E16; on E 16 it reached its highest point in the rhIGF-1 injected group. In ovo
administration of rhIGF-1 on E 3 appeared to delay myostatin expression approximately 1 day as compared to control embryos at
E 9, while it enhanced follistatin expression on E 9. Our results suggest that myostatin and follistatin genes may be pivotal regulators
of skeletal muscle growth, and that in ovo administration of rhIGF-1on E 3 may alter the expression profiles of myostatin and
follistatin genes, which might enhance the skeletal muscle mass of quail embryos.
Key Words: Myostatin, follistatin, quail embryos, in ovo rhIGF-1

Myostatin ve Follistatin Genlerinin Ekspresyon Profilinin B›ld›rc›n (Coturnix coturnix)
Embriyolar›nda in ovo rhIGF-1 Etkisiyle De¤iflimi
Özet: Myostatin, ba¤lay›c› proteini Follistatin ile beraber, özel olarak çizgili kas geliflimini hem embriyo ve hemde postnatal dönemde
engelledi¤i, buna ra¤men, Insulin-like growth factor-1 (IGF-1) büyüme faktörünün çizgili kaslarla beraber tüm embriyo büyümesini
stimule etti¤i bildirilmifltir. Bu çal›flmada büyüme faktörlerinin ayr› ayr› expresyon profilini belirlemek ve embriyonal geliflimin 3’üncü
gününde yap›lan in ovo recombinant human (rh) IGF-1 (100 ng/embriyo) injeksiyonunun bu genler üzerine etkisi araflt›r›ld›. Bu
cal›flmada, 400 adet fertilize olmufl b›ld›rc›n yumurtas› kullan›lm›flt›r. Kontrol ve injekte edilmifl guruplar için ayr› ayr› olmak üzere,
embriyonal geliflimin ilk 6 gününde (E 3 ile E 6 aras›) embriyonun tamam›ndan, 7. ve 8. günde (E 7 ve E 8) gö¤üs ve kar›n k›sm›ndan,
9-16. günlerde ise (E 9 ile E 16 aras›) sadece gö¤üs kaslar›ndan RNA’lar elde edildi. Daha sonra, büyüme faktörlerine ait cDNA’lar,
Reverse-Transcription Polymerase Chain Reaction (RT-PCR) tekni¤i kullan›larak ekspresyon profili ç›kart›ld›. Follistatin gen
expresyonu en erken E 3’de görülmesine ra¤men, myostatin gen ekspresyonu E 5’de gözlemlendi. Kontrol gurubu b›ld›rc›n
embriyolar›nda, myostatin mRNA miktar› E 10’da bafllamak üzere E 12’ye kadar giderek azalmas›na ra¤men, in ovo rhIGF-1 injekte
edilmifl b›ld›rc›n embriyolar›nda, myostatin mRNA miktar› E 9’da dahada artarak E 16’da en yüksek seviyeye varm›flt›r. Bu araflt›rma
sonuçlar›, myostatin ve follistatin genlerinin b›ld›rc›nlar›n embriyonik çizgili kas gelifliminde önemli bir düzenleyici olabilece¤i ve
embriyonal geliflimin 3’üncü gününde yap›lan in ovo rhIGF-1 injeksiyonunun bu genlerin ekspresyon profilini de¤ifltirerek daha fazla
kas yap›m›na yol açabilece¤ini önermektedir.
Anahtar Sözcükler: Myostatin, follistatin, b›ld›rc›n embriyosu, in ovo rhIGF-1
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Introduction
Insulin-like growth factor-1 (IGF-1) is a well known
general enhancer of lean tissue growth, which acts both
on an endocrine and paracrine mechanisms. Transgenic
mice overexpressing IGF-1 have demonstrated general
hyperplasia (1), whereas muscular hypertrophy has been
observed when overexpression of IGF-1 is restricted to
muscles (2). Additionally, in ovo administration of
recombinant human IGF-1 (rhIGF-1, 100 ng/per embryo)
on embryonic day 3 significantly increased postnatal
muscle growth in 42-day-old chickens (3,4).
Myostatin, a member of the TGF-β family of growth
factors, is a negative regulator of skeletal muscle growth
(5). Mice lacking the myostatin gene have increased
muscle mass, and some of the double-muscled cattle
breeds possess mutations in the myostatin coding
sequence (6,7). In contrast, follistatin has been proposed
to be a positive regulator of skeletal muscle growth, as
mice lacking the follistatin gene have decreased muscle
mass, while mice overexpressing follistatin has resulted in
the double-muscled phenotype that is similar to
myostatin-null mice (8). Furthermore, follistatin is found
to attenuate myostatin binding to its receptors (Act RIIB
receptors), suggesting that follistatin binds myostatin to
inhibit its function.
Myostatin and follistatin gene expressions have been
detected in the very early stage of development in mice
and chicken embryos (9,10). Additionally, in ovo
administration of rhIGF-1 (100 ng/per embryo) on
embryonic day 3 significantly altered the myostatin gene
expression pattern during chicken embryonic
development (11). Thus, the present study was
conducted to determine the effect of in ovo
administration of rhIGF-1 (100 ng/per embryo, on
embryonic day 3) on temporal expression patterns of
myostatin and follistatin genes during quail
embryogenesis, with an emphasis on pectoralis muscle
development.

Materials and Methods
Injection Procedure
Fertilized quail eggs (Coturnix coturnix) were
obtained from the Poultry Facilities of Kafkas University
(Kars, Turkey). The injection procedure has been
previously described (3). Briefly, 100 ng/100 µl of rhIGF-
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1 in 10 mM acetic acid, 0.1% BSA was administered, per
egg, through the blunt end of the egg on embryonic day
3. Prior to injection, the blunt end of the egg was
sterilized with 70% ethanol. A dental drill bit was used to
create a single hole, without penetrating the
chorioallantoic membrane. Both rhIGF-1 and vehicle were
injected into the albumen with a 22-gauge needle. The
hole was sealed with an sticker. Eggs were set in a
Buckeye incubator/hatcher (temperature: 37 °C ± 0.5 °C;
humidity: 86% to 87%).
Tissue collection
Embryos and tissues were harvested in compliance
with the approved Kafkas University Animal Care and Use
Committee Protocol. The method of tissue collection has
been previously described (11). Briefly, all the embryos
were isolated and washed free of yolk, albumen, and
extra-embryonic membranes with sterile, nuclease-free
water. Whole embryos were collected on each of the
embryonic days (E) 3 to 6 (n = 6 per day). Cranial halves
of embryos, consisting of the lumbosacral level to the
neck, without head, were collected on E 7 and E 8 (n =
6 per day). Pectoralis muscle was collected on E 9
through E 16 (n = 4 per day). All the tissue collections
were performed at consistent times on each sampling day
throughout the experimental period, beginning on E 3
and then every 24 h until E 16.
RNA extraction and RT-PCR
Total RNA was extracted from all of the tissues
mentioned above using the Tri-Reagent (Sigma, St. Louis,
MO,
USA)
modification
of
the
guanidine
isothiocyanate/phenol-chloroform method as described by
Chomczynski and Sacci (12). The RNA concentration was
estimated using a GeneQuant RNA/DNA Calculator
(BioChrom Ltd., Cambridge, UK). Samples of RNA were
stored at -20 °C.
Reverse transcription (RT) was performed by adding 2
µg of total RNA to 2 µg of Oligo dT primers and sterile
nuclease-free dd H2O, to make a final volume of 15 µl.
The samples were heated at 70 °C for 5 min and then
immediately cooled to 4 °C for 2 min. Reverse
transcription buffer containing dNTPs (final concentration
of each was 10 mM), 25 units of RNase inhibitor, and 200
units of Maloney murine leukemia virus reverse
transcriptase (Promega, Madison, WI, USA) were added
to each sample. The sample, with a final volume of 40 µl,
was incubated at 37 °C for 1 h followed by incubation at
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95 °C for 5 min. For the PCR reaction, 1 µl of RT reaction
mixture was added to 25 µl of solution containing 2.5 µl
of Taq buffer, 0.25 µl Taq DNA polymerase (Ampli-taq
Gold, ABI, Foster City, CA, USA), 2.5 µl dNTPs (final
concentration of each was 2 mM), 2.5 µl each of forward
and reverse primers, and 14.75 µl of sterile nuclease-free
H2O. The PCR reaction began with 1 cycle at 94 °C for 5
min, an annealing step at 60 °C for myostatin or 55 °C for
follistatin and β-actin for 1 min and extension at 72 °C for
10 min. The first cycle was followed by another 25 cycles
consisting of 30-s intervals at 94 °C, followed by 60 °C
for myostatin or 55 °C for follistatin and β-actin, followed
by 72 °C. As a control, a PCR reaction without c-DNA was
run and no contamination in the reaction mixture was
found (data not shown).
PCR primers
All PCR primers were made by Alpha DNA (Montreal,
Canada). Primers for myostatin were designed on the
basis of published sequences of chicken myostatin (13).
The sequence of the forward primer was 5'
GACTATCATGCCACAACCGAGACGA 3', while the reverse
primer was 5' GTGTACCAGGTGAGTGTGCGGGTATT 3'.
Forward and reverse primers predicted a PCR product of
657 base pairs (bp), which corresponds to bases 327984 of the sequence. Primers for follistatin were
designed on the basis of the published sequence of
chicken follistatin (14). The sequence of the forward
primer was 5' CATCCCGTGCAAAGAAAC 3', while the
reverse primer was 5'CTCGTAGGCTAATCCAATG 3'.
These primers amplified a PCR product of 445 bp, as
previously reported (15), which corresponded to bases
260-705 of the sequence. Primers for β-actin were
used to amplify a 285 bp product, as previously
published (16), as an internal standard to verify the
level of amplification. The sequence of the forward
primer was 5' TCATGAAGTGTGACGTTGACATCCGT 3',
while
the
reverse
primer
was
5'
CCTAGAAGCATTTGCGGTGCACGATG 3'.
The amplified PCR products for each gene were
visualized on 1.5% agarose gels stained with ethidium
bromide. Products were analyzed by densitometry of the
stained gels, and data should, therefore, be considered
semi-quantitative. The identity of all PCR products was
confirmed by sequence analysis. Mean gene values for
each sampling day were derived from a minimum of 4
individual sample collections and a minimum of 3
independent cDNA and RT-PCR amplifications per
sample.

Results
Figure 1 depicts the patterns of β-actin gene
expression in both control and in ovo rhIGF-1 injected
quail embryos. β-actin was used as a house-keeping gene
and expression levels were stable throughout the
experiment in both groups, for each corresponding day.
Myostatin gene expression was first seen in 5-day-old
quail embryos and then gradually increased through E 9,
in both the control and in ovo rhIGF-1 injected groups
(Figure 2). Myostatin mRNA levels from the in ovo rhIGF-1
injected group pectoralis muscles continued to increase on
E 10 (~ 3-fold) and then sharply decreased on E 11.
Levels then began to increase and reached the highest
level on E 16. Myostatin mRNA levels in control pectoralis
muscle declined from E 10 to E 12, and then sharply
increased on E 13 (~ 5-fold). Levels in control pectoralis
muscle remained high until E 16, though there was a
sudden decrease on E 14 (Figure 2). Follistatin gene
expression was first seen in 3-day-old quail embryos in
both the control and in ovo rhIGF-1 injected groups
(Figure 3). Follistatin mRNA levels in the control group
remained at this level until E 13, on which day there was
an approximately 11-fold increase (Figure 3). Follistatin
mRNA levels in the control group remained at this level,
although it suddenly decreased on E 14 (~ 2-fold).
Follistatin mRNA levels from the in ovo rhIGF-1 injected
group increased on E 9 (~ 9-fold) and continued to
increase, reaching the highest level on E 10. Levels then
sharply declined and remained at this level until E 16
(Figure 3).

Discussion
Myostatin and follistatin are both secreted proteins
involved in the control of muscle mass during embryonic
development. They have opposite effects on muscle
growth; as documented by genetic models, the potential
function of follistatin is as a positive regulator of muscle
differentiation, whereas myostatin is a negative regulator
of skeletal muscle growth (8). Endocrine studies have
demonstrated that IGFs, particularly IGF-1, are involved
in controlling muscle growth, as well as overall growth
(2). In the light of these findings, it is expected to see that
myostatin and follistatin gene expression patterns should
initially overlap in control groups. In ovo rhIGF-1
administration on E 3 enhances follistatin gene expression
while depressing myostatin gene expression. However, as
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Figure 1. Representative steady-state levels of the control (A) and rhIGF-1 treated (B) groups’ β-actin mRNA in whole embryo and pectoralis muscle
during quail embryonic development (n = 6 or 4 per day, respectively). The bands for β-actin mRNA were analyzed by densitometry and
the integration values (mean ± SD) were expressed in arbitrary densitometric units on each sampling day.
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Figure 2. Representative steady-state levels of the control (A) and rhIGF-1 treated (B) groups’ myostatin mRNAs in whole embryo and pectoralis
muscle during quail embryonic development (n = 6 or 4 per day, respectively). The bands for myostatin mRNA were analyzed by
densitometry and the integration values (mean ± SD), after normalization to β-actin, were expressed in arbitrary densitometric units on
each sampling day.
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Figure 3. Representative steady-state levels of the control (A) and rhIGF-1 treated (B) groups’ follistatin mRNAs in whole embryo and pectoralis
muscle during quail embryonic development (n = 6 or 4 per day, respectively). The bands for follistatin mRNA were analyzed by
densitometry and the integration values (mean ± SD), after normalization to β-actin, were expressed in arbitrary densitometric units on
each sampling day.

shown in Figures 2 and 3, myostatin and follistatin gene
expression patterns did not exactly overlap in the control
group. These results are consistent with findings of
transgenic animal studies. For example, follistatin
transgenic
animals
overexpressing
follistatin
demonstrated increased muscle mass, which was much
greater than the increase in myostatin null mice (8),
suggesting that the effects of follistatin may be the result
of the inhibition of a ligand other than myostatin.
Secondly, although overall myostatin expression
patterns in both the control and in ovo rhIGF-1 injected
groups were similar during both whole embryo and
embryonic pectoralis muscle development, in ovo
administration of rhIGF-1 on E 3 appeared to delay
myostatin expression approximately 1 day compared to
control embryos at E 9 (Figure 2), while enhancing
follistatin expression on E 9 (Figure 3). A delay of
myostatin expression would allow myoblasts additional
time in the replicative phase of the cell cycle, which would
ultimately lead to increased muscle fiber formation. Thus,
delayed expression of myostatin may cause muscle
hyperplasia in quail embryos, as seen in postnatal chicken

skeletal muscle increase due to in ovo rhIGF-1
administration (3,4).
We have detected myostatin mRNA in quail embryos
as young as 5 days old in both the control and rhIGF-1
injected groups, in contrast to our previous findings in
chicken embryos (10). This could be due to the
differences between quail and chicken embryonic
development. On the other hand, we assume that early
myostatin expression (E 5) in the present study
originated from presumptive myoblasts, given the fact
that skeletal muscle tissue is the main source of myostatin
(5). However, this assumption does not preclude the
possibility of myostatin expression generated from other
early embryonic tissues, because myostatin mRNA was
detected in adipose tissues and in chicken embryos,
before the myogenic lineage was established (10,17).
Thus, further studies using in situ hybridization should be
carried out to clarify the exact origin of myostatin gene
expression in early quail embryonic development.
In vitro studies have shown that IGF-1 up-regulates
myogenic regulatory factors (MRF, MyoD, Myogenin, and
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Myf-5), which are thought to play important roles in the
growth of muscle fibers (18). MRFs bind to an E-box
(19). Given the fact that myostatin gene has an E-box in
its upstream region (20), IGF-1 may down-regulate
myostatin if MRFs compete with other transcriptional
factors that up-regulate it. However, considering the
complexity of the IGF system, such as the secretion of
binding proteins and the presence of 2 surface receptors,
it is difficult to pin-point the exact mechanism by which a
single in ovo rhIGF-1 injection altered developmental

expression patterns of myostatin and follistatin genes
during chicken embryonic development.
In conclusion, our results demonstrate that in ovo
administration of rhIGF-1 on E 3 altered developmental
expression patterns of myostatin and follistatin genes. A
complete understanding of the interaction between IGF-1
and the myostatin and follistatin genes during embryonic
development could be beneficial to food animal
agriculture.
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